HC Wainwright Predicts Immunome’s Q2 Earnings (NASDAQ:IMNM)

Immunome, Inc. (NASDAQ:IMNM) – Investment analysts at HC Wainwright raised their Q2 2026 earnings estimates for Immunome in a research note issued on Wednesday, May 13th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($0.48) per share for the quarter, up from their previous estimate of ($0.55). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.50) per share. HC Wainwright also issued estimates for Immunome’s Q3 2026 earnings at ($0.51) EPS, Q4 2026 earnings at ($0.53) EPS, FY2026 earnings at ($1.99) EPS and FY2027 earnings at ($1.72) EPS.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.12.

Other equities research analysts have also issued research reports about the company. Wall Street Zen lowered Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Immunome in a research note on Thursday, January 15th. Stephens lowered their price target on Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Truist Financial upgraded Immunome to a “strong-buy” rating in a research report on Monday, May 4th. Finally, Craig Hallum upped their price objective on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Immunome currently has a consensus rating of “Moderate Buy” and an average price target of $33.45.

Immunome Stock Performance

Immunome stock opened at $22.02 on Friday. The stock has a market cap of $2.49 billion, a P/E ratio of -9.25 and a beta of 2.11. Immunome has a fifty-two week low of $7.62 and a fifty-two week high of $27.65. The firm’s fifty day moving average price is $21.99 and its 200-day moving average price is $21.19.

Hedge Funds Weigh In On Immunome

A number of large investors have recently modified their holdings of the company. Stoneridge Investment Partners LLC lifted its position in Immunome by 5.4% in the 3rd quarter. Stoneridge Investment Partners LLC now owns 12,174 shares of the company’s stock worth $143,000 after buying an additional 620 shares during the last quarter. ANTIPODES PARTNERS Ltd raised its stake in shares of Immunome by 6.1% during the third quarter. ANTIPODES PARTNERS Ltd now owns 10,892 shares of the company’s stock worth $128,000 after acquiring an additional 631 shares in the last quarter. Creative Planning raised its stake in shares of Immunome by 4.0% during the third quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after acquiring an additional 710 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Immunome by 14.4% in the 4th quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock worth $159,000 after acquiring an additional 935 shares during the last quarter. Finally, California State Teachers Retirement System lifted its holdings in shares of Immunome by 1.8% in the 4th quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock worth $1,439,000 after acquiring an additional 1,167 shares during the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Immunome news, insider Jack Higgins sold 9,438 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $21.64, for a total transaction of $204,238.32. Following the sale, the insider owned 22,000 shares in the company, valued at $476,080. This trade represents a 30.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Max Rosett sold 65,000 shares of Immunome stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $21.92, for a total value of $1,424,800.00. Following the sale, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at approximately $1,184,491.04. This trade represents a 54.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 139,438 shares of company stock worth $2,964,664. Corporate insiders own 7.21% of the company’s stock.

More Immunome News

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $40 price target on Immunome, signaling continued confidence in the company’s longer-term growth prospects. Immunome (NASDAQ:IMNM) Given “Buy” Rating at HC Wainwright
• Positive Sentiment: HC Wainwright improved its earnings outlook for FY2026 and FY2027, while also raising its estimates for Q2, Q3, and Q4 2026, suggesting analysts see a slightly better path to profitability than before.
• Positive Sentiment: Lifesci Capital also raised its FY2026 and Q2/Q3/Q4 2026 EPS estimates, adding to the generally constructive tone around Immunome’s near-term financial trajectory.
• Neutral Sentiment: Lifesci Capital’s FY2027 EPS estimate came in at a slightly improved loss forecast, but the company is still expected to remain unprofitable next year.
• Negative Sentiment: Not all revisions were upbeat: Lifesci Capital trimmed its Q4 2026 EPS estimate slightly, and consensus still points to sizable losses for the year, which may limit near-term upside.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.